Table 4. Logistic regression model of concordance between WFO and clinical use for patients receiving adjuvant chemotherapy after surgery (N=1,301).
| Variable | Univariate Cox regression | Multivariable Cox regression | |||
|---|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Adjusted odds ratio (95% CI) | P value | ||
| Age at diagnosis, years | |||||
| ≤40 (reference) | 1.00 | 1.00 | |||
| 41–50 | 1.07 (0.73–1.56) | 0.741 | 1.10 (0.72–1.69) | 0.665 | |
| 51–60 | 0.80 (0.54–1.17) | 0.251 | 0.99 (0.54–1.81) | 0.964 | |
| 61–70 | 0.49 (0.32–0.75) | 0.001 | 0.61 (0.31–1.21) | 0.159 | |
| 70+ | 0.34 (0.18–0.629) | <0.001 | 0.33 (0.14–0.78) | 0.012 | |
| Menopausal status | |||||
| Premenopausal (reference) | 1.00 | 1.00 | |||
| Postmenopausal | 0.61 (0.47–0.78) | <0.001 | 0.69 (0.41–1.13) | 0.140 | |
| Pathological TNM stage | |||||
| I (reference) | 1.00 | 1.00 | |||
| II | 1.80 (1.37–2.35) | <0.001 | 2.12 (1.57–2.88) | <0.001 | |
| III | 11.64 (6.74–20.11) | <0.001 | 13.87 (7.66–25.11) | <0.001 | |
| Ki-67 | |||||
| <14% (reference) | 1.00 | 1.00 | |||
| 14–50% | 1.28 (0.86–1.90) | 0.222 | 1.44 (0.69–3.02) | 0.329 | |
| >50% | 2.86 (1.86–4.40) | <0.001 | 1.75 (0.81–3.75) | 0.154 | |
| Molecular subtype | |||||
| Luminal A (reference) | 1.00 | 1.00 | |||
| Luminal B/HER2 negative | 0.90 (0.57–1.43) | 0.659 | 0.54 (0.23–1.26) | 0.153 | |
| Luminal B/HER2 positive | 3.28 (1.85–5.85) | <0.001 | 1.77 (0.70–4.51) | 0.23 | |
| HER2 positive | 2.84 (1.57–5.15) | 0.001 | 1.80 (0.70–4.60) | 0.223 | |
| Triple negative | 6.75 (3.49–13.07) | <0.001 | 5.95 (2.25–15.75) | <0.001 | |
| Vessel invasive status | |||||
| No (reference) | 1.00 | 1.00 | |||
| Yes | 2.32 (1.63–3.30) | <0.001 | 1.44 (0.954–2.17) | 0.082 | |
Potential confounders: age, menopausal status, TNM stage, molecular subtype, Ki-67 status, and vessel invasive status. WFO, Watson for Oncology.